Direct-acting antiviral (DAA) combinations are potent and effective drugs currently recommended for treatment of chronic HCV infection. Difficult to treat genotypes are the most important predictors of treatment failure. We report a case of DAA treatment failure in an HCV-infected patient carrying a recombinant genotype 2k/1b. This strain, first isolated from a Russian patient in 2002, has now been observed for the first time in Italy.
References
1.
Benítez-GutiérrezL., BarreiroP., LabargaP.Prevention and management of treatment failure to new oral hepatitis C drugs.Expert Opin Pharmacother2016; 17: 1215–1223.
2.
MorelV., FournierC., FrançoisC.Genetic recombination of the hepatitis C virus: clinical implications.J Viral Hepat2011; 18: 77–83.
3.
FrançoisC., CastelainS., DuverlieG., CapronD., Nguyen-KhacE.Optimizing the treatment of chronic viral hepatitis C.Expert Rev Gastroenterol Hepatol2009; 3: 607–613.
4.
SmithD.B., BukhJ., KuikenC.Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource.Hepatology2014; 59: 318–327.
5.
SmithD.B., PathiranaS., DavidsonF.The origin of hepatitis C virus genotypes.J Gen Virol1997; 78: 321–328.
6.
KalininaO., NorderH., MukomolovS., MagniusL.O.A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg.J Virol2002; 76: 4034–4043.
7.
ColinaR., CasaneD., VasquezS.Evidence of intratypic recombination in natural populations of hepatitis C virus.J Gen Virol2004; 85: 31–37.
8.
KageyamaS., AgdamagD.M., AlesnaE.T.A natural inter-genotypic (2b/1b) recombinant of hepatitis C virus in the Philippines.J Med Virol2006; 78: 1423–1428.
9.
NoppornpanthS., LienT.X., PoovorawanY., SmitsS.L., OsterhausA.D., HaagmansB.L.Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus.J Virol2006; 80: 7569–7577.
10.
Legrand-AbravanelF., ClaudinonJ., NicotF.New natural intergenotypic (2/5) recombinant of hepatitis C virus.J Virol2007; 81: 4357–4362.
11.
RossR.S., VerbeeckJ., ViazovS., LemeyP., Van RanstM., RoggendorfM.Evidence for a complex mosaic genome pattern in a full-length hepatitis C virus sequence.Evol Bioinform Online2008; 4: 249–254.
12.
MorenoP., AlvarezM., LópezL.Evidence of recombination in hepatitis C virus populations infecting a hemophiliac patient.Virol J2009; 6: 203–211.
13.
LeeY.M., LinH.J., ChenY.J.Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: full-length sequences of two new subtype 6w strains and a recombinant form_2b6w.J Med Virol2010; 82: 57–68.
14.
CaladoR.A., RochaM.R., ParreiraR., PiedadeJ., VenennoT., EstevesA.Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal.J Med Virol2011; 83: 608–615.
15.
European Association for Study of Liver.EASL Recommendations on Treatment of Hepatitis C 2015.J Hepatol2015; 63: 199–236.
16.
PaolucciS., FiorinaL., PirallaA.Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients.Virol J2012; 9: 245–252.
17.
PaolucciS., FiorinaL., MarianiB.Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients.Virol J2013; 10: 355–361.
18.
PohjanpeltoP., LappalainenM., WidellA., AsikainenK., PaunioM.Hepatitis C genotypes in Finland determined by RFLP.Clin Diagn Virol1996; 7: 7–16.
19.
TamuraK., PetersonD., PetersonN., StecherG., NeiM., KumarS.MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.Mol Biol Evol2011; 28: 2731–2739.
20.
GuindonS., DufayardJ.F., LefortV., AnisimovaM., HordijkW., GascuelO.New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0.Syst Biol2010; 59: 307–321.
21.
SchuermansW., OrlentH., DesombereI.Heads or tails: genotyping of hepatitis C virus concerning the 2k/1b circulating recombinant form.Int J Mol Sci2016; 17: pii E1384.
